In a setback for Human Genome Sciences, the FDA said that questions regarding the human data collected on its anthrax drug made it impossible "to make a complete judgment about whether raxibacumab should be licensed for marketing...." An expert panel meeting scheduled to review the therapy today will not be asked whether raxibacumab should be approved, restricting its conversation to animal studies. Report